Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

The Cannigma

SEPTEMBER 21, 2021

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 119

Patients Research and Development Sleep Clinical Trials 119

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

DECEMBER 9, 2021

The Financing is expected to close on December 10, 2021. The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JUNE 21, 2021

The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain. RYAH examined reporting from 17,313 such patients over the course of about 3 ½ years.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

DECEMBER 23, 2021

Findings in The Pharmaceutical Cannabis Report: 2nd Edition include: The author estimates the market size for the three most widely used cannabinoid pharmaceuticals (Epidiolex, Sativex, Dronabinol) to be worth just under €900 million as of 2021, growing to €1.8 billion by 2025. via inhalation of combusted flower).

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

LifeCannMD

MAY 27, 2025

Fernando Fandio-Sende, LifeCannMD After thirty years practicing medicine and specializing as a Miami cannabis doctor , I’ve had countless conversations with patients who tell me the same thing: “Doctor, I want to try medical marijuana , but I’m scared of getting too high.”

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

AUGUST 13, 2021

Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. Karl Hanes reported on 7 patients with TRD who described relief from depressive symptoms with continued oral consumption of salvia leaves three times a week. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Highlights from the presentation include: Declining PSA levels in treated patients. Phase 2 trial underway. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

The Cannigma

APRIL 12, 2023

In 2021, MoreBetter used its web-based software to track over 350 people using a CBN tincture from CBDistillery. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. It also, allegedly, helps with sleep (more on that below).

Sleep 137

Sleep Data Tincture Collective 137

Cannabis Law Report

JANUARY 11, 2022

Legal cannabis partnership to help patient access. The new distributor in the Australian medicinal cannabis industry – The Entourage Effect – has signed a firstof its kind deal with innovative medical cannabis clinic MiDispensary. As part of the partnership, The Entourage Effect will sell exclusively to patients of MiDispensary.

Access 52

Access Patients Clinical Trials Legalization 52

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — SciSparc Ltd. OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain.

Patients 70

Patients Research and Development Clinical Trials Chronic Pain 70

Cannabis Law Report

JUNE 23, 2021

NEO: AWKN) began trading today, June 23, 2021, on the NEO Exchange Inc. The company has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021 (Bristol, London, and Manchester). David Nutt), starts in Q4 2021.

Clinical Trials 85

Clinical Trials Therapy Research and Development Treatment 85

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. The May 4, 2021 guidance for revenue was in the range of $2.5 – $2.7 That has been increased as of June 17, 2021, to a range of $3.0

Pharmaceutical 83

Pharmaceutical Clinical Trials Therapy Programs 83

The Cannigma

MARCH 7, 2022

A recent 2021 review of the literature found that there is simply no substantial evidence to back CBN’s claim to sedation and that more human research is needed. What can the current clinical trials tell us?

THC 140

THC Clinical Trials Sleep Cannabinoids 140

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Puff Puff Post

OCTOBER 3, 2019

Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders. Epidiolex proved tremendously successful in treating epilepsy patients. The possibility of treating the symptoms associated with autism originated when the FDA approved Epidoliolex in 2018.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Joyce Cutler, Texas the Latest State to Legalize Psychedelic Medical Research, BLOOMBERG LAW (June 23, 2021), available at [link].

Law 81

Law Therapy Clinical Trials Decriminalization 81

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

SEPTEMBER 6, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. during 2021-2026. The global medical cannabis market exhibited strong growth during 2015-2020.

Chronic Pain 66

Chronic Pain Research and Development Clinical Trials Epilepsy 66

Cannabis Law Report

JUNE 11, 2021

NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Here’s the press release.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

Veriheal

MAY 16, 2022

Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc. , Studying Ketamine Use for Parkinson’s Disease Patients. As many as 250 clinics across the U.S.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

OCTOBER 4, 2021

September 30, 2021. One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

JULY 6, 2021

London, UK – 5 July 2021. David Bradley, Chief Executive of South London and Maudsley NHS Foundation Trust, said, “We believe this collaboration could accelerate much-needed research that will translate into evidence-based and direct patient care for people who use our services. George Goldsmith, CEO and Co?

Research and Development 76

Research and Development Clinical Trials Therapy Patients 76

TheAnswerPage

JUNE 19, 2021

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. 29 May 2021 [link]. Sandip Patel, Reid Grinspoon, Bradley Fleming, Lauren A.

Clinical Trials 40

Clinical Trials Epilepsy Treatment CBD 40

Cannabis Law Report

OCTOBER 15, 2021

DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention.

Clinical Trials 40

Clinical Trials Research and Development Data Patients 40

TheAnswerPage

NOVEMBER 29, 2021

What serious adverse events have been noted in psilocybin clinical trials? The serious adverse events (AE) reported in the psilocybin clinical trial conducted by Compass Pathways occurred in 12 of the 233 patients and included suicidal behavior, suicidal ideation, and intentional self-injury. See the Answer.

Clinical Trials 40

Clinical Trials Events Patients 40

Veriheal

MAY 25, 2023

million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 75.52% to $3871.44 Ketamine Clinics Are an Evolutionary Addition to U.S. Healthcare Ketamine therapy has delivered positive results for patients when used in a structured outpatient setting. Globally, the ketamine market was worth USD $132.43

Medicine 98

Medicine Blood Pressure Therapy Clinical Trials 98

Cannabis Law Report

OCTOBER 20, 2021

A House subcommittee asked the Department of Veterans Affairs directors why they didn’t support a bipartisan bill ordering the department to conduct clinical trials on the potential benefits of medical marijuana. In response, they argued the VA Medicinal Cannabis Research Act ( H.R.

Hemp 52

Hemp Clinical Trials CBD Legalization 52

TheAnswerPage

NOVEMBER 30, 2021

Psilocybin, the hallucinogen found in “magic mushrooms” has been used in clinical trials. Schedule I substances cannot be used in clinical trials n the US (without special permission). Is psilocybin classified as a scheduled substance under the Controlled Substances Act? THC is also a schedule I substance.)

Clinical Trials 40

Clinical Trials Safety Treatment THC 40

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 45

Clinical Trials Epilepsy Pharmaceutical Treatment 45